CZ298511B6 - Použití benzocykloheptapyridinových sloucenin proprípravu farmaceutického prípravku pro použití v kombinaci s antineoplastickým lécivem a/nebo radioterapií k lécení proliferacních onemocnení - Google Patents

Použití benzocykloheptapyridinových sloucenin proprípravu farmaceutického prípravku pro použití v kombinaci s antineoplastickým lécivem a/nebo radioterapií k lécení proliferacních onemocnení Download PDF

Info

Publication number
CZ298511B6
CZ298511B6 CZ20002236A CZ20002236A CZ298511B6 CZ 298511 B6 CZ298511 B6 CZ 298511B6 CZ 20002236 A CZ20002236 A CZ 20002236A CZ 20002236 A CZ20002236 A CZ 20002236A CZ 298511 B6 CZ298511 B6 CZ 298511B6
Authority
CZ
Czechia
Prior art keywords
alkyl
substituted
aryl
compound
mpk
Prior art date
Application number
CZ20002236A
Other languages
Czech (cs)
English (en)
Other versions
CZ20002236A3 (cs
Inventor
R. Bishop@Walter
J. Catino@Joseph
J. Doll@Ronald
Ganguly@Ashit
Girijavallaihan@Viyyoor
Kirschmeier@Paul
Liu@Ming
L. Nielsen@Loretta
L. Cutler@David
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27385940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CZ298511(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of CZ20002236A3 publication Critical patent/CZ20002236A3/cs
Publication of CZ298511B6 publication Critical patent/CZ298511B6/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CZ20002236A 1997-12-22 1998-12-21 Použití benzocykloheptapyridinových sloucenin proprípravu farmaceutického prípravku pro použití v kombinaci s antineoplastickým lécivem a/nebo radioterapií k lécení proliferacních onemocnení CZ298511B6 (cs)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99602797A 1997-12-22 1997-12-22
US14352998A 1998-08-28 1998-08-28
US18196998A 1998-10-29 1998-10-29

Publications (2)

Publication Number Publication Date
CZ20002236A3 CZ20002236A3 (cs) 2001-04-11
CZ298511B6 true CZ298511B6 (cs) 2007-10-24

Family

ID=27385940

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20002236A CZ298511B6 (cs) 1997-12-22 1998-12-21 Použití benzocykloheptapyridinových sloucenin proprípravu farmaceutického prípravku pro použití v kombinaci s antineoplastickým lécivem a/nebo radioterapií k lécení proliferacních onemocnení

Country Status (25)

Country Link
EP (1) EP1041985B1 (cg-RX-API-DMAC7.html)
JP (1) JP4502503B2 (cg-RX-API-DMAC7.html)
KR (1) KR100700907B1 (cg-RX-API-DMAC7.html)
CN (1) CN1129431C (cg-RX-API-DMAC7.html)
AR (1) AR017440A1 (cg-RX-API-DMAC7.html)
AT (1) ATE317697T1 (cg-RX-API-DMAC7.html)
AU (1) AU756762B2 (cg-RX-API-DMAC7.html)
BR (1) BR9814419A (cg-RX-API-DMAC7.html)
CA (1) CA2315693C (cg-RX-API-DMAC7.html)
CL (1) CL2007001889A1 (cg-RX-API-DMAC7.html)
CO (1) CO5080764A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ298511B6 (cg-RX-API-DMAC7.html)
DE (1) DE69833509T2 (cg-RX-API-DMAC7.html)
DK (1) DK1041985T3 (cg-RX-API-DMAC7.html)
ES (1) ES2255196T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0102473A3 (cg-RX-API-DMAC7.html)
IL (1) IL136462A0 (cg-RX-API-DMAC7.html)
MY (1) MY137303A (cg-RX-API-DMAC7.html)
NO (1) NO326832B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ504928A (cg-RX-API-DMAC7.html)
PE (1) PE20000042A1 (cg-RX-API-DMAC7.html)
PT (1) PT1041985E (cg-RX-API-DMAC7.html)
SK (1) SK285584B6 (cg-RX-API-DMAC7.html)
TW (1) TW581763B (cg-RX-API-DMAC7.html)
WO (1) WO1999032114A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
PT1233787E (pt) * 1999-11-09 2005-04-29 Conseils Rech S Et D Applic Sc Produto contendo um inibidor da transducao dos sinais das proteinas g heterotrimericas em associacao com um outro agente anticanceroso para utilizacao terapeutica no tratamento do cancro
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
CA2397690A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
CA2397256A1 (en) * 2000-02-29 2001-09-07 Mary Ellen Margaret Rybak Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
AU2001242434A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
JP2003525237A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗腫瘍性アントラサイクリン誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
WO2001064217A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
AU2001246477A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
AU2002236813A1 (en) * 2001-01-22 2002-07-30 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
WO2002064142A1 (en) * 2001-02-15 2002-08-22 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with antiestrogen agents
WO2003047697A2 (en) * 2001-11-30 2003-06-12 Schering Corporation Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
EP1453513A1 (en) * 2001-12-03 2004-09-08 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
CN105198758A (zh) * 2015-09-22 2015-12-30 湖南大学 一种高纯度(z)-他莫昔酚的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011034A1 (en) * 1990-12-18 1992-07-09 The Wellcome Foundation Limited Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
WO1997023478A1 (en) * 1995-12-22 1997-07-03 Schering Corporation Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
WO1997045412A1 (en) * 1996-05-30 1997-12-04 Merck & Co., Inc. A method of treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
JP2767176B2 (ja) * 1992-12-15 1998-06-18 大塚製薬株式会社 抗癌剤
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
DE69635114T2 (de) * 1995-08-09 2006-03-02 Banyu Pharmaceutical Co., Ltd. Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids
PL189698B1 (pl) * 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
WO1997036583A1 (en) * 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0910385A4 (en) * 1996-04-15 1999-12-22 Univ Pennsylvania Sensitization of cells to radiation and chemotherapy
WO1997038664A2 (en) * 1996-04-18 1997-10-23 Merck & Co., Inc. A method of treating cancer
US6337992B1 (en) * 1997-01-29 2002-01-08 Philips Medical Systems Technologies Ltd. Predictive bolus tracking
DE69837754T2 (de) * 1997-02-18 2008-02-07 Canji, Inc., San Diego Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011034A1 (en) * 1990-12-18 1992-07-09 The Wellcome Foundation Limited Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
WO1997023478A1 (en) * 1995-12-22 1997-07-03 Schering Corporation Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
WO1997045412A1 (en) * 1996-05-30 1997-12-04 Merck & Co., Inc. A method of treating cancer

Also Published As

Publication number Publication date
HUP0102473A2 (hu) 2002-01-28
HUP0102473A3 (en) 2003-07-28
DE69833509D1 (de) 2006-04-20
ES2255196T3 (es) 2006-06-16
CL2007001889A1 (es) 2008-01-11
CA2315693C (en) 2010-11-30
SK285584B6 (sk) 2007-04-05
EP1041985B1 (en) 2006-02-15
CN1284875A (zh) 2001-02-21
CO5080764A1 (es) 2001-09-25
IL136462A0 (en) 2001-06-14
CN1129431C (zh) 2003-12-03
WO1999032114A1 (en) 1999-07-01
CZ20002236A3 (cs) 2001-04-11
AU756762B2 (en) 2003-01-23
SK8982000A3 (en) 2001-04-09
MY137303A (en) 2009-01-30
TW581763B (en) 2004-04-01
PT1041985E (pt) 2006-07-31
PE20000042A1 (es) 2000-02-17
BR9814419A (pt) 2000-10-10
CA2315693A1 (en) 1999-07-01
KR100700907B1 (ko) 2007-03-29
NO20003229D0 (no) 2000-06-21
KR20010033452A (ko) 2001-04-25
NO326832B1 (no) 2009-02-23
JP4502503B2 (ja) 2010-07-14
DK1041985T3 (da) 2006-06-19
DE69833509T2 (de) 2006-10-26
NZ504928A (en) 2004-12-24
EP1041985A1 (en) 2000-10-11
NO20003229L (no) 2000-08-22
ATE317697T1 (de) 2006-03-15
AR017440A1 (es) 2001-09-05
AU1907299A (en) 1999-07-12
JP2001526224A (ja) 2001-12-18

Similar Documents

Publication Publication Date Title
US6333333B1 (en) Methods for treating proliferative diseases
ES2275505T3 (es) Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores.
AU2024205010A1 (en) CSF1R inhibitors for use in treating cancer
ES2216327T3 (es) Uso de iminoazucares alquilados para tratar la resistencia a multiples a farmacos.
CZ20002236A3 (cs) Použití benzocykloheptapyridinových sloučenin v kombinaci s antineoplastickými léčivy pro přípravu kombinovaného léčiva k léčení proliferačních onemocnění
JP2006503867A (ja) 癌を処置するための相乗的な方法および組成物
TW202207939A (zh) 單一療法及組合療法
ES2253890T3 (es) Uso de compuestos de vitamina pp.
US6777415B2 (en) Methods of inducing cancer cell death and tumor regression
CN1511036B (zh) 包含信号转导抑制剂和埃坡霉素衍生物的联合形式
KR20240122783A (ko) Fgfr 저해제 및 kras 저해제를 포함하는 병용 요법
AU2002211862A1 (en) Methods of inducing cancer cell death and tumor regression
CN105246480A (zh) 使用4-氨基-2-(2,6-二氧代-哌啶-3-基)-异吲哚啉-1,3-二酮治疗和控制中枢神经系统癌症的方法和组合物
US8022056B2 (en) Compositions and methods for the treatment of cancer
ES3038469T3 (en) Quinoline derivative and epirubicin used for soft tissue sarcoma combination therapy
JP2008523104A (ja) 癌を治療するための新規なファルネシルタンパク質トランスフェラーゼ阻害剤およびその使用
MXPA00006257A (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
TW201121547A (en) Pharmaceutical composition for the treatment of proliferative diseases
HK1141447A1 (en) Pharmaceutical composition for the treatment of proliferative diseases
HK1141447B (en) Pharmaceutical composition for the treatment of proliferative diseases

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20101221